Renaissance Technologies LLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Renaissance Technologies LLC boosted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 33.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,351,640 shares of the company's stock after acquiring an additional 342,300 shares during the quarter. Renaissance Technologies LLC owned 0.91% of Xeris Biopharma worth $3,041,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers increased its holdings in Xeris Biopharma by 6.9% during the second quarter. Rhumbline Advisers now owns 189,970 shares of the company's stock valued at $427,000 after buying an additional 12,332 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Xeris Biopharma by 4,512.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company's stock valued at $37,000 after purchasing an additional 15,929 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Xeris Biopharma by 23.0% during the second quarter. Bank of New York Mellon Corp now owns 428,554 shares of the company's stock valued at $964,000 after purchasing an additional 80,015 shares during the last quarter. Rosalind Advisors Inc. increased its holdings in shares of Xeris Biopharma by 10.6% in the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company's stock worth $7,020,000 after buying an additional 300,000 shares during the last quarter. Finally, Simplicity Wealth LLC purchased a new stake in Xeris Biopharma during the second quarter valued at approximately $27,000. Institutional investors own 42.75% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 price target on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Stock Performance

Xeris Biopharma stock traded down $0.08 during mid-day trading on Tuesday, hitting $2.77. The company's stock had a trading volume of 1,575,158 shares, compared to its average volume of 1,752,161. The company has a 50 day moving average of $2.66 and a 200-day moving average of $2.28. Xeris Biopharma Holdings, Inc. has a one year low of $1.46 and a one year high of $3.26. The stock has a market cap of $412.73 million, a PE ratio of -6.06 and a beta of 2.76.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The company had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same quarter in the previous year, the firm posted ($0.14) earnings per share. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.4 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.